

Clinical Trial in Adolescents with Fragile X

The Child Development Unit at The Children's Hospital at Westmead is participating in a clinical trial testing a new treatment for Fragile X syndrome in adolescents. The treatment is a capsule and the medication is taken twice daily for up to 16 weeks.

To be eligible to participate in the trial, patients must fit the following criteria:

- Be aged 12-17 in otherwise good general health.
- Have a previous diagnosis of Fragile X based on genetic testing (full mutation)
- Have a caregiver who spends on average at least 6 hours a day with the study participant and is willing to supervise treatment, attend all study visits and assist with study assessments
- Have a documented intellectual disability (IQ score less than 70)

The study lasts for a total of 20 weeks and includes a 3-week screening period, 16 weeks during which patients will receive study drug or placebo and a one week follow up. All patients will receive a placebo at some stage during the study.

If you would like more details on the trial, please contact Dr Natalie Silove at the Child Development Unit on 9845 2829.